Table 4 Kaplan-Meier median progression-free survival (PFS) and overall survival (OS) estimates for patients with and without early tumor shrinkage
Early tumor shrinkage at 6 weeks | p-value | |||
|---|---|---|---|---|
<10 % | ≥10 % | |||
GEMOX | PFS (months) median (95 % CI) | 2.5 (1.7-3.2) | 5.4 (2.0-8.9) | 0.03 |
GEMOX plus erlotinib | PFS (months) median (95 % CI) | 1.3 (1.0-1.6) | 8.3 (5.7-11.0) | 0.00 |
Overall | PFS (months) median (95 % CI) | 2.1 (0.9-3.3) | 7.3 (5.6-8.9) | 0.00 |
Early tumor shrinkage at 6 weeks | p-value | |||
<10 % | ≥10 % | |||
GEMOX | OS (months) median (95 % CI) | 4.8 (1.6-7.9) | 9.5 (7.5-11.4) | 0.03 |
GEMOX plus erlotinib | OS (months) median (95 % CI) | 6.4 (3.1-9.6) | 11.4 (7.6-15.2) | 0.00 |
Overall | OS (months) median (95 % CI) | 5.8 (3.0-8.5) | 10.7 (8.9-12.6) | 0.00 |